Zydus Cadila gets sANDA approval from USFDA for manufacturing of Doxycycline Injection

16 Jul 2020 Evaluate
Zydus Cadila has received approval for its supplemental Abbreviated New Drug Application (sANDA) for Doxycycline Injection USP, 100 mg/Vial from the US Food and Drug Administration (USFDA). The product will be manufactured at Cadila Healthcare’s injectable facility at Jarod, Vadodara (formerly known as Liva Pharmaceuticals). The state-of-the-art facility is equipped with manufacturing lines that can handle both liquid and lyophilised products based on vials and cartridges presentation.

Doxycycline USP is the first product approval at the second combined Liquid plus Lyophilised Vials Injectable line at the Jarod facility. This facility is an important one for Zydus’ US Injectable portfolio as five ANDAs have been approved from this facility and another six have been filed, awaiting approval. Zydus has plans to file further ANDAs and NDAs from this facility. This approval will also help ramp up site transfer approvals from the Moraiya facility to this facility.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×